The Washington Times Surgeries to manage obesity “declined substantially” for eligible patients starting in 2023, fueled by surging prescriptions for appetite-suppressing GLP-1 drugs, a new study finds.
Surgeries to manage obesity “declined substantially” for eligible patients starting in 2023, fueled by surging prescriptions for appetite-suppressing GLP-1 drugs, a new study finds.